Loading...
•
Jun 30
Cerus Q2 2025 Earnings Report
Cerus Corporation announced strong financial results for the second quarter of 2025, with record product revenue and positive non-GAAP adjusted EBITDA.
Key Takeaways
Cerus Corporation reported a robust second quarter in 2025, achieving record product revenue of $52.4 million, a 16% increase year-over-year. The company also posted positive non-GAAP adjusted EBITDA of $0.9 million and narrowed its net loss attributable to Cerus. This strong performance led to an upward revision of full-year 2025 product revenue guidance.
Total revenue for Q2 2025 reached $60.1 million, marking a 19% increase compared to the prior year.
Product revenue hit a record $52.4 million, driven by significant growth in IFC and global platelet sales.
The company achieved positive non-GAAP adjusted EBITDA of $0.9 million for the quarter, continuing a positive trend.
Cerus raised its full-year 2025 product revenue guidance to a range of $200 million to $203 million, reflecting strong anticipated growth.
Cerus
Cerus
Cerus Revenue by Segment
Cerus Revenue by Geographic Location
Revenue by Segment
Product Revenue
CapyFin.comGovernment Contract Revenue
CapyFin.comRevenue by Geographic Location
North America Revenue
CapyFin.comEurope, Middle East and Africa Revenue
CapyFin.comOther Revenue
CapyFin.com Forward Guidance
Cerus Corporation has raised its full-year 2025 product revenue guidance, reflecting strong performance and anticipated growth in the second half of the year, particularly for IFC revenue.
Positive Outlook
- Full-year 2025 product revenue guidance raised to $200 million - $203 million.
- Increased IFC guidance for 2025 to between $16 million - $18 million.
- Anticipated strong sales trajectory for the second half of 2025.
- Commitment to achieving positive, full-year 2025 non-GAAP adjusted EBITDA.
- Continued progress in multiple geographies and across the INTERCEPT product portfolio.
Challenges Ahead
- No specific negative forward guidance points were explicitly stated in the report.
- Risks associated with the commercialization and market acceptance of new products like INT200.
- Uncertainties in the regulatory review process for INTERCEPT Blood System for Red Blood Cells (RBCs) in Europe.
- Risks related to the uncertain nature of DoD's funding and potential delays in activities.
- Potential impacts of macroeconomic developments on the manufacturing supply chain.
Revenue & Expenses
Visualization of income flow from segment revenue to net income